At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 129 enrolled
Drug / intervention
Panobinostatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkins Lymphoma After High-dose Chemotherapy With Autologous Stem Cell Transplant
In Brief
A Phase 2 clinical trial evaluating Panobinostat for Classical Hodgkin's Lymphoma. Completed, enrolled 129 participants across 46 sites in 13 countries.
Detailed Summary
This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant. Safety of panobinostat also was assessed. Other markers that may correlate with efficacy or safety were explored.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClassical Hodgkin's Lymphoma
CountriesAustralia, Belgium, Brazil, France, Germany, Israel, Italy, Malaysia, New Zealand, Singapore, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2008
Enrollment StartSep 2008
Primary CompletionAug 2013
TodayJul 2026
First PostedAug 27, 2008
Enrollment StartSep 16, 2008
Primary CompletionAug 12, 2013
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 17.8 years ago
Interventions
Panobinostatdrug
Panobinostat hard gelatin capsules.